|
|
| (8 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| '''For patient information, click [[Breast cancer (patient information)|here]]'''
| | #REDIRECT [[Breast cancer]] |
| __NOTOC__
| |
| {{SI}}
| |
| {{CMG}} {{AE}} {{MV}}
| |
|
| |
| {{SK}} Intraductal hyperplasia; IDH; Atypical ductal hyperplasia; Comedocarcinoma; Duct cell carcinoma; Duct carcinoma
| |
|
| |
| ==Overview==
| |
| | |
| '''Ductal carcinoma''' is the most common type of breast cancer in women. Ductal carcinoma may be classified according to the Armed Forces Institute of Pathology (AFIP) into 2 groups: large cell carcinoma in situ and small cell carcinoma in situ. The pathogenesis of ductal carcinoma is characterized by the microinvasion of cancer cells limited to the ducts with no extension beyond the basement membrane. The mutation on HER2/neu has been associated with the development of ductal carcinoma.
| |
| | |
| ==Historical Perspective==
| |
| Ductal carcinoma was first described by MacCarthy in 1893.<ref name="name"> MacCarty WC. The histogenesis of cancer (carcinoma) of the breast and its clinical significance. Surg Gynecol Obstet 1913;17:441–59.</ref>
| |
| | |
| ==Classification==
| |
| *Ductal carcinoma may be classified according to the Armed Forces Institute of Pathology (AFIP) into 2 groups:
| |
| | |
| :*'''Large cell'''
| |
| ::*More aggressive form
| |
| ::*Also referred to as comedocarcinoma
| |
| :*'''Small cell'''
| |
| ::*Less aggressive
| |
| ::*Subtypes include cribriform, micropapillary, papillary, and solid in situ.
| |
| | |
| *Other variants of ductal carcinoma include, non-DCIS entities.
| |
| | |
| ==Pathophysiology==
| |
| *The pathogenesis of ductal carcinoma is characterized by the microinvasion of cancer cells limited to the ducts with no extension beyond the basement membrane.
| |
| *The mutation on HER2/neu has been associated with the development of ductal carcinoma.
| |
| *On gross pathology, characteristic findings of ductal carcinoma, include:
| |
| :*White
| |
| :*Firm stellate lesion
| |
| *On microscopic histopathological analysis, characteristic findings of ductal carcinoma, include:
| |
| :*Equal spacing of cells - "cookie cutter" look.
| |
| :*Cells line-up along lumen/glandular spaces - form "Roman briges".
| |
| :*Nuclear enlargement (key feature)
| |
| | |
| ==Causes==
| |
| *The most important cause of ductal carcinoma is mutations in the BRCA1/BRCA2 genes.
| |
| | |
| ==Differentiating ductal carcinoma from other Diseases==
| |
| *Ductal carcinoma must be differentiated from other diseases that cause nipple discharge, breast skin color change, and palpable mass such as:
| |
| :*Periductal mastitis
| |
| :*Breast lipoma
| |
| :*Inflammatory carcinoma of breast
| |
| :*Phyllodes tumour
| |
| | |
| ==Epidemiology and Demographics==
| |
| * The prevalence of ductal carcinoma is approximately 32.5 per 100,000 women worldwide.
| |
| ===Age===
| |
| *Ductal carcinoma is commonly observed among females between 40 to 80 years old
| |
| *Ductal carcinoma is rarely observed among males between 60 and 70 years of age
| |
| *Ductal carcinoma is more commonly observed among postmenopausal women
| |
| | |
| ===Gender===
| |
| *Females are significantly more commonly affected with ductal carcinoma than males.
| |
| | |
| ===Race===
| |
| *There is no racial predilection for ductal carcinoma.
| |
| | |
| ==Risk Factors==
| |
| *Common risk factors in the development of ductal carcinoma, include:
| |
| :*Family history of breast cancer
| |
| :*Mutations in BRCA1/BRCA2 genes
| |
| :*Previous exposure to radiation therapy
| |
| :*Increased breast density
| |
| :*Hormonal therapy
| |
| :*Nulliparity
| |
| :*Genetic syndromes (eg. Li-Fraumeni, Cowden syndrome)
| |
| :*Obesity
| |
| | |
| == Natural History, Complications and Prognosis==
| |
| *The majority of patients with ductal carcinoma remain asymptomatic for years.
| |
| *Early clinical features include skin color change or nipple discharge.
| |
| *If left untreated, the majority of patients with ductal carcinoma may progress to develop lymph node invasion, and metastasis.
| |
| *The most common complication of ductal carcinoma is lymphedema.
| |
| *Prognosis generally depends on the histological subtype.
| |
| :*In general, the 20-year mortality rate among patients with ductal carcinoma is approximately 3.3%.
| |
| :*Factors related with worse prognosis, include: young age at diagnosis, black ethnicity, and high grade cancer.
| |
| | |
| == Diagnosis ==
| |
| === Symptoms ===
| |
| *Ductal carcinoma is usually asymptomatic.
| |
| *Symptoms of ductal carcinoma may include the following:
| |
| :*Nipple discharge
| |
| ::*Skin color changes
| |
| ::*Warm and thickened
| |
| :*Skin of an orange appearance
| |
| :*Nipple retraction
| |
| | |
| === Physical Examination ===
| |
| *Patients with ductal carcinoma usually are well-appearing.
| |
| :*Physical examination may show no specific physical findings.
| |
| *In some cases, it may be remarkable for:
| |
| :*Palpable mass
| |
| | |
| === Laboratory Findings ===
| |
| *Laboratory findings consistent with the diagnosis of ductal carcinoma, include:
| |
| :*Positive/negative estrogen receptor (ER) and progesterone receptor (PR) expression
| |
| | |
| ===Imaging Findings===
| |
| *Mammography is the imaging modality of choice for ductal carcinoma.
| |
| *On mammography, findings of ductal carcinoma, include:
| |
| :*Calcifications (most common)
| |
| :*Simple mass
| |
| :*Soft-tissue opacity
| |
| :*Asymmetry without calcification
| |
| *The image below demonstrates findings compatible with ductal carcinoma.
| |
| <gallery>
| |
| Image:Mammo breast cancer.jpg|Normal (left) versus cancerous (right) mammography image.
| |
| </gallery>
| |
| *On ultrasound, findings of ductal carcinoma, include:
| |
| :*Microlobulated mild hypoechoic mass
| |
| | |
| === Other Diagnostic Studies ===
| |
| *Ductal carcinoma may also be diagnosed using biopsy.
| |
| *Indications for biopsy, include:
| |
| :*Lesion limited to one quadrant or section of the breast
| |
| | |
| == Treatment ==
| |
| === Medical Therapy ===
| |
| *The mainstay of therapies for ductal carcinoma are divided into 2 groups: hormonal therapy and targeted therapy.
| |
| '''Hormonal Therapy'''
| |
| :*Selective estrogen receptor modulators, such as:
| |
| :*Tamoxifen
| |
| :*Raloxifene
| |
| '''Targeted Therapy'''
| |
| :*HER2-directed therapy
| |
| :*Trastuzumab
| |
| *The primary goal of medical therapy is to reduce the risk of ipsilateral or contralateral breast invasion and also decreases the risk of recurrence.
| |
| | |
| === Surgery ===
| |
| *Surgery is the mainstay of therapy for ductal carcinoma.
| |
| *Surgical approaches for ductal carcinoma, include: mastectomy or breast-conserving therapy
| |
| *Lumpectomy in conjunction with adjuvant chemotherapy or radiation is the most common approach to the treatment of ductal carcinoma (with negative margins)
| |
| *Mastectomy is recommended for patients with extensive margins of ductal carcinoma.
| |
| | |
| === Prevention ===
| |
| *Effective measures for the secondary prevention of ductal carcinoma include: screening mammography for women between 50-74 years (or earlier if identified risk factors) and periodical breast self-examination (BSE).<ref name="preventive> US Task Preventive Force. http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/breast-cancer-screening Accessed on April 19, 2016</ref>
| |
| *Once diagnosed and successfully treated, patients with ductal carcinoma are followed-up every 3, 6, or 12 months depending on individual assessment.
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
|
| |
| [[Category:Oncology]]
| |
| [[Category:Types of cancer]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |